Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05090904 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

A Phase 2 study, sponsored by Insmed Incorporated.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target

NCT05090904: Completed Phase 2 study, sponsored by Insmed Incorporated.

NCT05090904 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05090904, a Phase 2 study, has completed, sponsored by Insmed Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target

Study Summary

The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.

Interventions

  • DRUG Placebo
  • DRUG Brensocatib

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2021-11-30
Est. Completion 2022-11-01
Phase Phase 2
Insmed Incorporated

31 total trials

What the finished NCT05090904 record still lists

NCT05090904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05090904 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05090904 about?

NCT05090904 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis". The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treat...

What is the current status of trial NCT05090904?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-11-30. Estimated completion is 2022-11-01.

What interventions are being tested in trial NCT05090904?

The interventions under investigation include: Placebo (DRUG), Brensocatib (DRUG).

Who is sponsoring clinical trial NCT05090904?

This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05090904's enrollment target sits among peer trials

29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05090904, the US trial registry maintained by the National Library of Medicine. NCT05090904 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.